Hypoxic Immunoselected UC-MSC Expansion for Therapeutic EVs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for degenerative musculoskeletal diseases such as osteoarthritis, degenerative disc disease, and osteoporosis fail to provide consistent pain relief, leading to high failure rates and the need for surgical solutions, while mesenchymal stem cell therapies show promise but require improved processing methods for enhanced therapeutic outcomes.
Innovation Solution
Isolation and expansion of umbilical cord-derived mesenchymal stem cells (UC-MSCs) under hypoxic conditions or with a prolyl hydroxylase (PHD) enzyme inhibitor, followed by immunoselection and processing to produce extracellular vesicles (EVs) for therapeutic products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for degenerative musculoskeletal diseases, then pain relief is provided temporarily, but treatment failure rate is high and surgical intervention is required
Solution Approach 1:
The patent changes the physiological parameters during MSC expansion by implementing hypoxic conditions (reduced oxygen tension) and controlling pH levels, which transforms the cellular environment to enhance survival and therapeutic efficacy, thereby improving treatment reliability and reducing failure rates
2Productivity
If MSCs are expanded under normoxic conditions, then expansion is faster, but MSC survival rate and therapeutic outcomes are reduced
Solution Approach 1:
The patent applies parameter changes by shifting from normoxic to hypoxic conditions during MSC expansion, creating an optimized physiological environment that simultaneously supports cell proliferation and enhances survival rates, thereby resolving the contradiction between expansion speed and therapeutic quality
3Reliability
If immunoselection is performed to purify MSC populations, then therapeutic outcomes are improved, but processing complexity increases
Solution Approach 1:
The patent uses immunomagnetic beads as an intermediary tool to facilitate immunoselection of MSCs. These beads bind to specific surface markers on MSCs, enabling selective isolation and purification through magnetic separation, which simplifies the overall process while maintaining high therapeutic efficacy
Data Source
AI summary
Disclosed herein are methods for isolation and expansion of umbilical cord-derived mesenchymal stem cells (UC-MSCs) having one or more cell surface markers, and compositions comprising such UC-MSCs. Also disclosed herein are further processing methods for use in connection with the UC-MSCs to isolate extracellular vesicles (EVs) therefrom. Also disclosed herein are lyophilized EVs isolated from the UC-MSCs, and adapted for use as a therapeutic product.